HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Neurogene (NASDAQ:NGNE) and maintained a price target of $51.
June 20, 2024 | 10:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Neurogene and maintained a price target of $51.
The reiteration of a Buy rating and a maintained price target of $51 by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100